The global clinical trial imaging market size was estimated at USD 1.23 billion in 2024 and is projected to reach USD 1.91 billion by 2030, growing at a CAGR of 7.8% from 2025 to 2030. Market growth is primarily driven by the expansion of the biotechnology and pharmaceutical sectors, along with rising investments in research and development aimed at developing novel therapeutics for diverse diseases.
Medical imaging continues to play a vital role in the advancement of innovative life science products. Despite the dynamic and evolving nature of the imaging industry, the biopharmaceutical and medical device sectors are experiencing sustained growth, supported by substantial investments and strategic mergers and acquisitions. These M&A activities increasingly focus on integrating advanced imaging technologies to enhance the efficiency and precision of the clinical trial process.
The clinical trial imaging market is witnessing steady expansion, fueled by growing R&D activities in new drug and therapy development. With more than 400,000 registered clinical trials globally, the demand for robust imaging solutions has surged—particularly across oncology, cardiology, and neurology applications. The integration of AI-powered image analysis and advanced imaging modalities is expected to improve data accuracy and streamline clinical assessments. Furthermore, the COVID-19 pandemic accelerated the adoption of virtual imaging trials, with approximately 30% of clinical trials employing virtual methodologies by 2021, showcasing the sector’s adaptability and resilience during global disruptions.
Key Market Trends & Insights
- North America accounted for the largest share of the global clinical trial imaging market at 47.93% in 2024.
- Asia Pacific is projected to record the fastest growth rate of 8.4% during the forecast period.
- By modality, the computed tomography (CT) scan segment held the largest share at 25.87% in 2024.
- Based on therapeutic area, oncology dominated the market with a 23.63% share in 2024.
- By services, the reading and analytical services segment led the market with a 30.95% share in 2024 and is expected to grow at a CAGR of 8.4% from 2025 to 2030.
Download a free sample PDF of the Clinical Trial Imaging Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 1.23 Billion
- 2030 Projected Market Size: USD 1.91 Billion
- CAGR (2025–2030): 7.8%
- North America: Largest market in 2024
- Asia Pacific: Fastest growing market
Competitive Landscape
Leading market players are expanding their global presence through partnerships, collaborations, and acquisitions to enter new markets and strengthen technological capabilities. Collaborations with academic medical centers and research institutions, such as the Mayo Clinic, are becoming increasingly common as companies seek access to clinical expertise and real-world validation for their imaging technologies.
For example, in September 2023, GE HealthCare announced a strategic collaboration with the Mayo Clinic to drive innovation in medical imaging and theragnostics. This partnership aims to advance the development of new technologies and solutions that can enhance diagnostics, precision imaging, and patient care.
Recent Developments
- March 2023: Clario introduced a cloud-based image viewer designed specifically for clinical trials to improve medical image accessibility and streamline analysis workflows.
- May 2023: Cleerly partnered with ProScan Imaging to deliver personalized cardiac health solutions leveraging Cleerly’s AI-powered platform for analyzing coronary CT angiography (CCTA) images, supporting more precise cardiovascular diagnostics.
Key Companies Profiled
- IXICO plc
- Navitas Life Sciences
- Resonance Health
- ProScan Imaging
- Radiant Sage LLC
- Medpace
- Biomedical Systems Corp
- Cardiovascular Imaging Technologies
- Intrinsic Imaging
- BioTelemetry
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The global clinical trial imaging market is poised for steady expansion, supported by the growth of the biopharmaceutical sector, the integration of advanced imaging technologies, and the increasing adoption of AI-driven analytical tools. Rising global clinical trial volumes and the adoption of virtual imaging solutions are enhancing trial efficiency and accuracy. Strategic collaborations among key players and research institutions are further driving innovation and enabling improved clinical outcomes. With North America maintaining dominance and Asia Pacific emerging as a high-growth region, the market is set to achieve sustained momentum through 2030.
No comments:
Post a Comment